MyAverix Finance MyAverix Finance

US · Healthcare

Inhibikase Therapeutics Inc (IKT)

Biotechnology

Inhibikase Therapeutics Inc (IKT) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-03-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for IKT

P/E ratio
18.00

Inhibikase Therapeutics Inc (IKT) — FAQ

What is IKT's P/E ratio?

The price-to-earnings (P/E) ratio for Inhibikase Therapeutics Inc (IKT) is 18.00 (data as of 2026-03-23).

Does Inhibikase Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Inhibikase Therapeutics Inc (IKT). Check the MyAverix Finance app for the latest dividend data.

What sector is Inhibikase Therapeutics Inc in?

Inhibikase Therapeutics Inc (IKT) is classified in the Healthcare sector (Biotechnology industry).

What exchange is IKT listed on?

IKT is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play